

**REPORT ON USE OF FUNDS RAISED FROM
THE SHARE ISSUANCE TO INCREASE
CHARTER CAPITAL FROM VND
266.152.680.000 TO VND 306.075.580.000
AGIMEXPHARM
PHARMACEUTICAL JOINT-STOCK
COMPANY**



AGIMEXPHARM PHARMACEUTICAL JOINT-STOCK COMPANY

CONTENTS

	Page
1. Contents	1
2. Statement of the Board of Directors	2 - 4
3. Independent Auditor's Report	5 - 6
4. Report on use of funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000	7 - 8
5. Notes to the Report on use of funds from the share issuance	9 - 10



AGIMEXPHARM PHARMACEUTICAL JOINT-STOCK COMPANY

STATEMENT OF THE BOARD OF DIRECTORS

The Board of Directors of Agimexpharm Pharmaceutical Joint-Stock Company (hereinafter referred to as “the Company”) presents this statement together with the Report on use of funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000.

Business highlights

The Company is a joint stock company which has been operating under the Business Registration Certificate No. 1600699279, initially registered on 03 June 2004 and 21st amended on 27 January 2026, granted by An Giang Province Department of Finance.

Head office

- Address : No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam
- Tel. : (0296) 385 6961- 385 6964
- Fax : (0296) 385 7301

Affiliates:

Affiliates	Address
Branch of Agimexpharm Pharmaceutical Joint-Stock Company	No. 49-51-53, Street No. 3A, An Lac Ward, Ho Chi Minh City
Branch of Agimexpharm Pharmaceutical Joint-Stock Company	No. 42 Nguyen Sinh Sac Street, Hoa Khanh Ward, Da Nang City
Branch of Agimexpharm Pharmaceutical Joint-Stock Company – Agimexpharm Thoi Ward, An Giang Province	No. 66 Vu Trong Phung Street, Thanh An Cluster, My Pharmaceutical Manufacturing Factory
Branch of Agimexpharm Pharmaceutical Joint-Stock Company – Binh Hoa Factory	Lot C4, Binh Hoa Industrial Park, Binh Hoa Commune, An Giang Province
Agimexpharm Pharmaceutical Joint-Stock Company – Tay Nguyen Branch	No. 184/84 Giai Phong Street, Buon Ma Thuot Ward, Dak Lak Province
Branch of Agimexpharm Pharmaceutical Joint-Stock Company	No. 46, Lane 105, Lang Ha Street, Dong Da Ward, Hanoi City

Principal business activities of the Company are to manufacture medicines, pharmaceutical chemicals and medicinal herbs; to trade in optical, medical, dental and hospital equipment; to trade in medicines, pharmaceutical products; to trade in nutritious food; to manufacture and trade in cosmetics; to trade in materials and ancillary materials, pharmaceutical chemicals for pharmaceutical production; to trade in vaccines and medical biological products; to manufacture bottled water (the Company must comply with the Law on food safety and hygiene during operation course); to manufacture dietary supplements; to manufacture, trade in, and process essential oils from herbs; to manufacture, and trade in food, nutritional food, dietary supplements.

Board of Directors, Supervisory Board, and Board of Management

The Board of Directors, the Supervisory Board and the Board of Management of the Company during the period and as of the date of this statement include:



AGIMEXPHARM PHARMACEUTICAL JOINT-STOCK COMPANY**STATEMENT OF THE BOARD OF DIRECTORS (cont.)*****The Board of Directors***

Full name	Position	Appointing/re-appointing date
Ms. Pham Thi Bich Thuy	Chairwoman	Re-appointed on 08 April 2023
Mr. Nguyen Van Kha	Vice Chairman	Re-appointed on 08 April 2023
Ms. Tran Thi Dao	Member	Re-appointed on 08 April 2023
Mr. Nguyen Quoc Dinh	Member	Re-appointed on 08 April 2023
Mr. Pham Uyen Nguyen	Member	Re-appointed on 08 April 2023
Mr. Huynh Hoang Ha	Member	Appointed on 08 April 2023

The Supervisory Board

Full name	Position	Appointing/re-appointing/resigning date
Ms. Tran Thi Thanh Hang	Head of the Board	Re-appointed on 08 April 2023
Ms. Nguyen Hong Ngoc	Member	Re-appointed on 08 April 2023
Ms. Nguyen Thi An	Member	Appointed on 27 March 2026
Ms. Pham Hai Yen	Member	Appointed on 08 April 2023 Resigned on 27 March 2026

The Board of Management

Full name	Position	Appointing/re-appointing date
Mr. Nguyen Van Kha	General Director	Re-appointed on 08 April 2023
Ms. Pham Thi Bich Thuy	Deputy General Director	Appointed on 02 January 2018
Mr. Lam Tri Hien	Deputy General Director	Appointed on 22 February 2019
Mr. Vu Minh Tuan	Deputy General Director	Appointed on 01 October 2019
Mr. Huynh Hoang Ha	Deputy General Director	Appointed on 01 January 2021
Mr. Le Van Mac	Deputy General Director	Appointed on 25 May 2026

Legal Representative

The Company's legal representative during the period and as of the date of this statement is Mr. Nguyen Van Kha – General Director (re-appointed on 08 April 2023).

Auditors

A&C Auditing and Consulting Co., Ltd. has been appointed to perform the audit on the Company's Report on use of funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000 of Agimexpharm Pharmaceutical Joint-Stock Company.

Responsibilities of the Board of Management

The Board of Management of the Company is responsible for the preparation of the Report on use of funds raised from the share issuance to increase charter capital from VND VND 266.152.680.000 to VND 306.075.580.000 to give a true and fair view of the use of funds raised from the share issuance of the Company.

The Board of Management is responsible for ensuring that the proper accounting books are properly maintained to fairly reflect the use of funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000, and for ensuring that the Report on use of funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000 has been properly prepared, and presents fairly and truly, in conformity with the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System, and the reporting convention.



3815-
IG TY
OÁN VÀ
A&C
HI NH
Y NAM
HÚ - T

AGIMEXPHARM PHARMACEUTICAL JOINT-STOCK COMPANY

STATEMENT OF THE BOARD OF DIRECTORS (cont.)

Approval of the Report on use of funds raised from the share issuance

The Board of Directors hereby approves the accompanying Report on use of funds raised from the share issuance, which gives a true and fair view of the use of funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000, in conformity with the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System, and relevant statutory requirements on preparation and presentation of the Report on use of funds raised from the share issuance.

For and on behalf of the Board of Directors,



Phạm Thị Bích Thủy
Chairwoman

Date: 16 June 2026

003.
NH
TỬ V
NH
BỘ
P. CẤY



A&C AUDITING AND CONSULTING CO., LTD.

Ho Chi Minh Head Office : 02 Truong Son St., Tan Son Hoa Ward, Ho Chi Minh City, Vietnam
Hanoi Branch : 40 Giang Vo St., Giang Vo Ward, Ha Noi City, Vietnam
Central Region Branch : Lot STH 06A01, Road 13, Le Hong Phong II Urban Area, Nam Nha Trang Ward, Khanh Hoa Province, Vietnam
Southwest Branch : 15-13 Vo Nguyen Giap St., Hung Phu Ward, Can Tho City, Vietnam

Tel: +84 (028) 3547 2972 kttv@a-c.com.vn
Tel: +84 (024) 3736 7879 kttv.hn@a-c.com.vn
Tel: +84 (0258) 246 5151 kttv.nt@a-c.com.vn
Tel: +84 (0292) 376 4995 kttv.ct@a-c.com.vn



www.a-c.com.vn

No. 4.0251/26/TC-AC

INDEPENDENT AUDITOR'S REPORT ON THE REPORT ON THE USE OF FUNDS RAISED FROM THE SHARE ISSUE TO INCREASE THE AUTHORISED CAPITAL FROM 266.152.680.000 VND to 306.075.580.000 VND OF AGIMEXPHARM PHARMACEUTICAL JOINT-STOCK COMPANY

**To: THE SHAREHOLDERS, THE BOARD OF DIRECTORS AND THE BOARD OF MANAGEMENT
AGIMEXPHARM PHARMACEUTICAL JOINT-STOCK COMPANY**

We have audited the accompanying Report on use of funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000 of Agimexpharm Pharmaceutical Joint-Stock Company (hereinafter referred to as "the Company"), which was prepared on 16 June 2026 (from page 07 to page 10).

Responsibility of the Board of Management

The Company's Board of Management is responsible for the preparation, true and fair presentation of the Report on use of funds raised from the share issuance in accordance with the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System, and relevant statutory requirements on the recognition of the Report on use of funds raised from the share issuance; and responsible for the internal control as the Board of Management determines necessary to enable the preparation and presentation of the Report on use of funds raised from the share issuance to be free from material misstatement due to fraud or error.

Responsibility of Auditors

Our responsibility is to express an opinion on the Report on use of funds raised from the share issuance based on our audit. We conducted our audit in accordance with the Vietnamese Standards on Auditing. Those standards require that we comply with ethical standards and requirements and plan and perform the audit to obtain reasonable assurance about whether the Report on use of funds raised from the share issuance is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the Report on use of funds raised from the share issuance. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Report on use of funds raised from the share issuance, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the preparation and true and fair presentation of the Report on use of funds raised from the share issuance in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Management, as well as evaluating the overall presentation of the Report on use of funds raised from the share issuance.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion of Auditors

In our opinion, the accompanying Report on use of funds raised from the share issuance gives a true and fair view, in all material respects, of the use of funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000 of Agimexpharm Pharmaceutical Joint-Stock Company, in conformity with the Vietnamese Accounting Standards, the Vietnamese Enterprise



Accounting System, and relevant statutory requirements on the preparation and presentation of the Report on use of funds.

Emphasis of matter

Without qualifying our opinion above, we would like to draw the readers' attention to Note II.3 to the Notes to the Report on use of funds raised from the share issuance to increase charter capital, which states that: This Report is intended solely for the purpose of reporting to the State management authorities in accordance with Circular No. 96/2020/TT-BTC dated 16 November 2020 of the Ministry of Finance providing guidance on information disclosure in the securities market. Accordingly, this Report should not be used for any other purpose or issued to any other parties. This Report is only related to the use of funds raised from the share issuance to increase the Company's charter capital, and not related to the whole Financial Statements of Agimexpharm Pharmaceutical Joint-Stock Company.



A&C Auditing and Consulting Co., Ltd.
Southwest Region Branch



Nguyen Huu Danh
Partner
Audit Practice Registration Certificate No. 1242-2023-008-1
Authorized Signatory

Nguyen Thuy Trang
Auditors
Audit Practice Registration Certificate No. 3592-2026-008-1

Can Tho City, 16 June 2026



AGIMEXPHARM PHARMACEUTICAL JOINT-STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**REPORT ON USE OF FUNDS RAISED FROM
THE SHARE ISSUANCE TO INCREASE CHARTER CAPITAL
FROM VND 266.152.680.000 TO VND 306.075.580.000****1. Overview of the share issuance to increase charter capital**

No.	Content	Information
1	Name of shares offered	: Shares of Agimexpharm Pharmaceutical Joint-Stock Company
2	Type of shares	: Common shares
3	Par value	: VND 10.000/share
4	Number of shares registered for offering	: 3.992.290 shares
5	Total expected funds to be raised	: VND 39.922.900.000 (at par value)
6	Issuance method	: Offering to existing shareholders
7	Issuance date	: 04/12/2025
8	Offering commencement date	: 04/12/2025
9	Offering completion date	: 06/01/2026
10	Subscription period	: From 04/12/2025 to 25/12/2025 and from 05/01/2026 to 06/01/2026
11	Total number of shares sold	: 3.992.290 shares

2. Funds raised from the share issuance

	<u>Value</u>
Number of shares	3.992.290
Selling price (VND/share)	25.000
Amount (VND)	99.807.250.000
In which:	
- Owner's capital (VND)	39.922.900.000
- Share premiums (VND)	59.884.350.000
Directly attributable costs of share issuance (VND)	479.800.000



AGIMEXPHARM PHARMACEUTICAL JOINT-STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

3. Report on use of funds in accordance with the planned use of funds under the share issuance plan

Pursuant to the Resolution 02/NQ-AGP.ĐHĐCĐ dated 25 August 2025 of the General Meeting of Shareholders of Agimexpharm Pharmaceutical Joint-Stock Company approving the plan for the public offering of additional shares to existing shareholders through written ballots.

Pursuant to the Resolution No. 13/NQ-AGP.HĐQT dated 29 August 2025 of the Board of Directors of Agimexpharm Pharmaceutical Joint-Stock Company approving the detailed plan for use of funds raised from the public offering of additional shares to existing shareholders.

Pursuant to the Resolution No. 02/NQ-AGP.HĐQT dated 09 January 2026 of the Board of Directors of Agimexpharm Pharmaceutical Joint-Stock Company approving the results of the public offering of additional shares to existing shareholders.

Pursuant to the Report No. 01/BC-AGP dated 09 January 2026 on the results of the public share offering of Agimexpharm Pharmaceutical Joint-Stock Company, submitted to the State Securities Commission of Vietnam.

Based on the actual operation, the funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000, the Company's use of funds as at 25 May 2026 is as follows:

No.	Content	Expected amount as per the plan (VND)	Amount used (VND)	Note
1	Repayment of borrowing from VietinBank – An Giang Branch	99.807.250.000	99.807.250.000	Debit note
	Total	99.807.250.000	99.807.250.000	

An Giang, 16 June 2026

Preparer

Do Thi Kim Len

Acting Chief Accountant

Pham Do Phuong Thao

General Director



Nguyen Van Kha

.9815-
NG TY
OÁN V
A&I
HI NH
Y NAM
HÚ - T

AGIMEXPHARM PHARMACEUTICAL JOINT-STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

NOTES TO THE

REPORT ON USE OF FUNDS RAISED FROM THE SHARE ISSUANCE TO INCREASE CHARTER CAPITAL FROM VND 266.152.680.000 TO VND 306.075.580.000

I. GENERAL INFORMATION

1. Ownership form

Agimexpharm Pharmaceutical Joint-Stock Company (hereinafter referred to as “the Company”) is a joint stock company.

2. Business fields

The Company’s business fields are industrial production and trading.

3. Principal business activities

The principal business activities of the Company are to manufacture medicines, pharmaceutical chemicals and medicinal herbs; to trade in optical, medical, dental and hospital equipment; to trade in medicines, pharmaceutical products; to trade in nutritious food; to manufacture and trade in cosmetics; to trade in materials and ancillary materials, pharmaceutical chemicals for pharmaceutical production; to trade in vaccines and medical biological products; to manufacture bottled water (the Company must comply with the Law on food safety and hygiene during operation course); to manufacture dietary supplements; to manufacture, trade in, and process essential oils from herbs; to manufacture, and trade in food, nutritional food, dietary supplements.

4. Normal operating cycle

The normal operating cycle of the Company is within 12 months.

5. Structure of the Company

Affiliates that are not legal entities

<u>Affiliates</u>	<u>Address</u>
Branch of Agimexpharm Pharmaceutical Joint-Stock Company	No. 49-51-53, Street No. 3A, An Lac Ward, Ho Chi Minh City
Branch of Agimexpharm Pharmaceutical Joint-Stock Company	No. 42 Nguyen Sinh Sac Street, Hoa Khanh Ward, Da Nang City
Branch of Agimexpharm Pharmaceutical Joint-Stock Company – Agimexpharm Pharmaceutical Manufacturing Factory	No. 66 Vu Trong Phung Street, Thanh An Cluster, My Thoi Ward, An Giang Province
Branch of Agimexpharm Pharmaceutical Joint-Stock Company – Binh Hoa Factory	Lot C4, Binh Hoa Industrial Park, Binh Hoa Commune, An Giang Province
Agimexpharm Pharmaceutical Joint-Stock Company – Tay Nguyen Branch	No. 184/84 Giai Phong Street, Buon Ma Thuot Ward, Dak Lak Province
Branch of Agimexpharm Pharmaceutical Joint-Stock Company	No. 46, Lane 105, Lang Ha Street, Dong Da Ward, Hanoi City



AGIMEXPHARM PHARMACEUTICAL JOINT-STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

II. ACCOUNTING CONVENTION FOR THE REPORT ON USE OF FUNDS RAISED FROM THE SHARE ISSUANCE TO INCREASE CHARTER CAPITAL FROM VND 266.152.680.000 TO VND 306.075.580.000

1. Accounting convention for the Report on use of funds raised from the share issuance

The accompanying Report on use of funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000 is prepared in Vietnamese Dong (VND), using the historical cost basis, in conformity with the applicable Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System, and relevant statutory requirements on preparation and presentation of the Report on the use of funds raised from the share issuance.

The Report on use of funds raised from the share issuance is prepared on the cash basis and constitutes a part of the Company's total cash inflow and outflow.

2. Reporting period

The Report on use of funds is prepared to reflect the use of funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000.

3. Reporting purposes

The Company's Report on use of funds raised from the share issuance to increase charter capital from VND 266.152.680.000 to VND 306.075.580.000 is intended solely for the purpose of reporting on the use of funds in accordance with the plan on use of funds approved by the Board of Directors of Agimexpharm Pharmaceutical Joint-Stock Company under the Resolution No. 13/NQ-AGP.HDQT dated 29 August 2025 regarding the approval of the plan for the use of funds expected to be raised from the public offering of additional shares, not extended to the whole Financial Statements of the Company.

The Report on use of funds raised from the share issuance is prepared for Agimexpharm Pharmaceutical Joint-Stock Company to meet the regulatory requirements. Therefore, this Report may not be appropriate to use for any other purposes.

An Giang, 16 June 2026

Preparer



Do Thi Kim Len

Acting Chief Accountant



Pham Do Phuong Thao

General Director



Nguyen Van Kha

